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Nobiletin is a fully methoxylated flavone that has demonstrated anticancer activity via 
multiple modes of action. In the present study, the metabolism and further 
antiproliferative activity of nobiletin was evaluated in the CYP1 expressing human 
breast cancer cell line MDA–MB–468 and the normal breast cell line MCF10A. 
Nobiletin was metabolized in MDA–MB–468 cells to a single-demethylated 
derivative assigned NP1. This metabolite was absent in MCF10A cells that did not 
express CYP1 enzymes. Nobiletin exhibited submicromolar IC50 (0.1±0.04 μM) in 
MDA–MB–468 cells, whereas it was considerably less active in MCF10A cells (40 
μM). In the presence of the CYP1 inhibitor acacetin, the conversion of nobiletin to 
NP1 was significantly reduced in MDA–MB–468 cells. Furthermore, a significant 
increase was noted in the population of the cells at the G1 phase, following treatment 
with nobiletin (10 μM) for 24 h compared with the control cells treated with DMSO 
(0.1%) alone (55.9±0.14 vs. 45.6±1.96), whereas the cell cycle of MCF10A cells was 
not significantly altered under the same treatment conditions. Taken collectively, the 
results suggest that nobiletin is selectively bioactivated in MDA–MB–468 breast 
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Flavonoids comprise a class of natural polyphenolic compounds with multiple 
anticancer properties (Zafar et al., 2017; Marrelli et al., 2015). Nobiletin is a 
flavonoid, which is a major constituent of citrus fruits, including oranges and 
tangerins (Kim et al., 2016; Ho and Kuo, 2014). Nobiletin can be found in the plants 
of the genus Citrus, and is particularly more abundant in the peel compared to the 
other edible parts of the fruit (Manthey and Grohmann, 2001). This compound has 
been examined extensively due to its potential cancer preventative activity. Nobiletin 
caused G2/M arrest in Hs578T breast cancer cells via downregulation of the Akt and 
MAPK cell signaling pathways (Borah et al., 2017), whereas it further induced 
autophagy in human gastric cancer SNU-16 cells via upregulation of the glucose 
regulated protein GRP78 and the ER-stress related proteins IRE1–α, ATF–4 and 
CHOP (Moon and Cho, 2016). In addition, the effects of nobiletin on the metastatic 
spread of cancer cells have been investigated and it was reported that this compound 
could downregulate the enzymatic activity of MMP–9 by inhibiting the PI3K/Akt 
pathway and prevent the TGF–β triggered migration and epithelial to mesenchymal 
transition via modulation of the Akt/GSK3β/β–catenin signaling (Miyata et al., 2017; 
Zhang et al., 2017). Moreover, nobiletin inhibited tumor angiogenesis in MCF7 breast 
cancer cells via Src, FAK and STAT3 signaling and in ovarian cancer cells by 
inhibition of VEGF, Akt, HIF–1α and NF–κB secretion, while it concomitantly 
decreased invasion, motility and migration via MMP–2 and MMP–9 downregulation 
in U2OS osteosarcoma cells (Sp et al., 2017; Chen et al., 2015; Cheng et al., 2016). In 
vivo, nobiletin demonstrated inhibition of colitis–associated colon carcinogenesis in 
azoxymethane/dextran sulfate sodium–treated mice via decreased expression of iNOS 
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and increased Nrf2 enzyme expression, whereas it inhibited the growth of H22 
transplantable hepatocellular tumor (Wu et al., 2017; Ma et al., 2014).  
In addition to the extensive profiling of nobiletin, in terms of inhibition of metastasis, 
invasion and proliferation, a previous study conducted by our research group 
demonstrated selective bioactivation of this compound by the cytochrome P450 CYP1 
family enzymes in MCF7 breast cancer cells (Surichan et al., 2012). The interactions 
of structurally similar dietary flavonoids with CYP1 enzymes have been investigated 
by recent studies and a cancer therapeutic effect of these compounds has been 
demonstrated in breast and liver cancer cells via their intracellular metabolism 
(Androutsopoulos et al., 2008; Androutsopoulos et al., 2009a; Androutsopoulos et al., 
2009b; Androutsopoulos et al., 2009c; Androutsopoulos et al., 2009d; 
Androutsopoulos et al., 2010; Androutsopoulos and Spandidos 2013; 
Androutsopoulos and Tsatsakis 2014). Flavonoids are oxidized to their corresponding 
hydroxylated derivatives via aromatic hydroxylation and/or demethylation reactions 
occurring on the B and/or A rings of the polyphenolic moiety and the resulting 
metabolites inhibit cancer cell growth at equivalent and/or higher levels compared 
with the corresponding parent compounds (Androutsopoulos et al., 2008; 
Androutsopoulos et al., 2009a; Androutsopoulos et al., 2009b; Androutsopoulos et al., 
2009d; Androutsopoulos and Spandidos, 2013; Androutsopoulos and Tsatsakis, 
2014). Nobiletin was previously shown to induce CYP1 enzyme activity and 
expression in MCF7 breast cancer cells that in turn caused metabolism of this 
compound to a major metabolite by a one step demethylation reaction (Surichan et al., 
2012).   
In the present study, the metabolism of nobiletin was investigated in the CYP1 
expressing breast cancer cell line MDA–MB–468 that expresses constitutively CYP1 
 7 
enzymes and the normal breast cell line MCF10A that is devoid of CYP1 expression. 
The data indicated that nobiletin was metabolized to the same major conversion 




2. Materials and Methods 
2.1 Chemicals and antibodies 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), propidium 
iodide (PI), α-napthoflavone, acacetin, tissue culture reagents and tissue culture media 
were purchased from Sigma Aldrich (St Louis, MO, USA). Nobiletin was purchased 
from Extrasynthese (Lyon, France).  
 
2.2 Cell culture  
Triple negative MDA–MB–468 cells were maintained in RPMI without phenol red in 
the presence of 10% FBS and 2 mM glutamine. MCF10A cells were grown in 
DMEM:F12 that contained the aforementioned supplements and additionally insulin 
(10 μg/ml), hydrocortisone (500 ng/ml) and EGF (20 ng/ml). The cells were grown in 
a humidified incubator at 37 C in 5% CO2 /95% air and passaged every 3 to 4 days 
using trypsin EDTA (0.25% v/v).  
 
2.3 Metabolic studies 
MDA–MB–468 and/or MCF10A cells were incubated with 10 μM of nobiletin for 24 
h or longer time points. At 24 h or 96 h time points, cell aliquots were obtained and 
the extraction of nobiletin and its metabolite(s) was conducted by addition of equal 
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volumes of methanol and acetic acid at a 100:1 ratio. The samples were centrifuged at 
3,500 g for 20 min at 4 C and the supernatants were analyzed by reversed phase 
HPLC.  
 
2.4 HPLC analysis 
The methodology has been described in detail in previous publications 
(Androutsopoulos et al., 2009a, Androutsopoulos et al., 2008). The separation was 
conducted on a Luna C18 4.6 x 150 mm 5 µ column with a mobile phase consisting of 
solvents A and B. Solvent A comprised 1% acetonitrile and 0.5% acetic acid in H2O 
and solvent B 4% acetonitrile and 0.5% acetic acid in CH3OH. The separation was 
conducted using gradient mixture of the solvents A and B as follows: 60% solvent A 
and 40% solvent B at time=0 min and 10% solvent A and 90% solvent B at time=10 
min. The composition of the solvents was adjusted to the initial conditions with 8 min 
remaining for column equilibration after each run. The detection of nobiletin 
concentration was monitored using a Waters Series 200 UV detector (Waters, 
Hertfordshire, UK) at 327 nm. The concentration of nobiletin was estimated by a 
calibration curve covering the range of 0.05–10 M. The assay was carried out at 37 
C and the flow rate was 1 ml/min. The average recovery for tangeretin was 90% and 
the retention time using the aforementioned parameters was 16.8 min.  
 
2.5 LC-MS analysis 
Mass spectrometry analysis of nobiletin was conducted on an Agilent 1100 Series 
LC/MSD Trap XCT systems with a photodiode array detector as described previously 
(Surichan et al., 2012). The LC parameters were the same as those used for the HPLC 
analysis. The photodiode array detector was set at 330 nm. The LC flow was 
controlled from the photodiode array detector into the mass spectrometer without 
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stream splitting. Nitrogen was used as the nebulizing gas at 60 psi and as drying gas 
with the flow rate of 10 L/min at 350˚C. Molecular ions ([M+H]+) were detected in 
the range of 200–500 using an auto–MS mode. The MS determination was acquired in 
electrospray ionisation (ESI) positive mode. The MS data were analyzed using 
LC/MSD Trap software 5.3. The Retention time (Rt) of nobiletin under these 
conditions was 16.8 min. 
 
 
2.6 MTT assay  
MDA–MB–468 and MCF10A cells (1 x 10
4
 cells/ml) were seeded in 96-well plates 
and the antiproliferative effect of nobiletin was examined as described previously 
(Androutsopoulos et al., 2008). Inhibition experiments were conducted in the 
presence of 0.5-1 μM α-napthoflavone and/or acacetin.  
 
2.7 FACS analysis 
MDA–MB–468 and MCF10A were grown in T25 flasks and were treated with 
nobiletin at a concentration of 10 μM in the presence and/or absence of CYP1 
inhibitors (0.5–1 μM) for 24 h. The cells were subsequently washed with PBS, 
removed by trypsin/EDTA and centrifuged at 3,500 rpm for 5 min. The cells were 
fixed in 70% ethanol for at least 24 h at –20 °C. The cells were incubated with PI (50 
μg/ml) and RNAse (100 μg/ml) for 30 min at 37 °C. Flow cytometry was conducted 
using a Beckman Coulter flow cytometer at PMT4 and at least 10,000 events were 
acquired for analysis. The Multicycle analysis 2.0 Software was used for the 




2.8 Statistical analysis 
The data were presented as the mean of at least three independent measurements and 
were analyzed by the paired t–test, the unpaired t–test and the One-Way analysis of 




3.1 CYP1 enzymes metabolize nobiletin in MDA–MB–468 human breast cancer cells 
The previous study conducted by our research group investigated the metabolism of 
nobiletin in MCF7 cells and/or MCF7 cells that were pre–induced with the potent 
CYP1 inducer TCDD (Surichan et al., 2012). In the present study, the investigation of 
nobiletin was carried out in MDA–MB–468 cells that express constitutively CYP1 
enzymes in the absence of an inducer (Androutsopoulos et al., 2008, Wilsher et al., 
2017). Incubation of nobiletin for 24 h with MDA–MB–468 cells resulted in an 
apparent decrease in the concentration of this compound, while a main metabolite 
denoted NP1 was present (Fig. 1A). This metabolite exhibited a retention time of 15.8 
min (Fig. 1A). In contrast to MDA–MB–468 cells, the incubation of nobiletin with 
MCF10A normal breast cells for 24 h revealed neither a significant decrease in the 
concentration of nobiletin, nor the production of the metabolite NP1 (Fig. 1A,B). The 
concentration of nobiletin was significantly reduced in MDA–MB–468 cells at the 24 
h time point, whereas no significant change was noted for MCF10A cells (Fig. 1B). 
The metabolism of this compound in MDA–MB–468 cells was evident from 1 h of 
incubation and gradually increased at the 3, 6 and 9 h time points, respectively (Fig. 





Figure 1. HPLC analysis of nobiletin following incubation with the human breast cell 
lines MDA–MB–468 and MCF10A. A starting concentration of 10 μM was used and 
the metabolism was investigated at 0, 3, 6, 9 and 24 h time points by HPLC as 
described in materials and methods. The experiments were conducted at least 3 times 
and error bars indicate STDEV of the mean. (A) HPLC chromatograms of nobiletin in 
the 2 breast cell lines at 0 (black color) and 24 h (red color) time points. (B) 
Measurement of the concentration of the parent compound and the metabolite NP1 in 
the 2 cell lines. Due to the unavailability of NP1 authentic standard the concentration 
of this compound was expressed in AU. (C) HPLC chromatograms of nobiletin in 
MDA–MB–468 cells at 0 (black color), 1 (blue color), 3 (green color), 6 (red color) 
and 9 (orange color) h time points. (D) Quantification of the concentration of 






Figure 2. LC-MS analysis of the metabolism of nobiletin in MDA–MB–468 and 
MCF10A cells. (A) LC chromatograms of the incubation of nobiletin with the MDA–
MB–468 and MCF10A cell lines at various time points (24, 96 h).  (B)  Mass 
spectrum of NP1 and nobiletin in the cell line incubates. 
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primary metabolite of nobiletin. The LC chromatogram of the assay matched that 
noted from the HPLC experiments with regard to the retention time of the 
compounds, whereas the MS analysis revealed that NP1 exhibited a molecular mass 
of 389 (Fig. 2A,B). 
    
3.2 Nobiletin is bioactivated in the CYP1–expressing cell line MDA–MB–468 
Previous studies have demonstrated that MDA–MB–468 cell constitutively express 
CYP1 enzymes compared with MCF10A cells that express little or no CYP1 protein 
(Androutsopoulos et al., 2008; Wilsher et al., 2017). The cytotoxicity of nobiletin was 
tested in the aforementioned 2 cell lines. This compound was considerably active in 
MDA–MB–468 cells and indicated a submicromolar IC50 (0.1±0.04 μM), whereas it 
demonstrated limited toxicity in MCF10A cells (40 μM) (Fig. 3A). This resulted in an 
activation factor of approximately 400 (IC50normal/IC50tumor) exhibiting favorable 
selectivity towards the breast cancer cells. 
The cytotoxicty of nobiletin in MDA–MB–468 cells was further investigated in the 
presence of the CYP1 inhibitors acacetin and α–napthoflavone (Fig. 3B). The IC50 of 
nobiletin was considerably increased from 0.1±0.04 μM to 30±2.4 μM μM in the 
presence of the CYP1 inhibitor acacetin (Fig. 3B). Similar results were noted for the 
use of α–napthoflavone as a CYP1 inhibitor. Furthermore, metabolic studies revealed 
that in the presence of the CYP1 inhibitors the conversion of NP1 from nobiletin was 
significantly reduced in MDA–MB–468 cells (Fig. 3C, D). The concentration of the 
parent compound nobiletin was reduced to a smaller extent in the presence of the 
CYP1 inhibitor (3.94±0.41 μM vs. 1.78±0.34 μM), whereas a significant decline in 




Figure 3. The bioactivation of tangeretin in the CYP1 expressing cell line MDA–MB–
468. Cell viability was measured using the MTT assay as determined in the materials 
and methods section. The experiments were conducted at least 3 times and error bars 
indicate STDEV of the mean. Cell survival plots indicating the IC50 determination of 
nobiletin in (A) MDA–MB–468 and MCF10A cells and (B) MDA–MB–468 and 
MCF10A cells in the presence and/or absence of the CYP1 inhibitor acacetin (0.5 
μM). Similar results were obtained when the CYP1 inhibitor α–napthoflavone was 
used. (C) The metabolism of nobieltin in MDA–MB–468 cells in the presence and/or 
absence of the CYP1 inhibitor acacetin (0.5 μM). HPLC chromatogram of MDA–
MB–468 cell incubation with tangeretin, in the presence and/or absence of acacetin 
(0.5 μM) for 24 h. (D) Quantification of the concentration of the compounds nobiletin 
and NP1 in MDA–MB–468 cells, in the presence and/or absence of the CYP1 
inhibitor acacetin (0.5 μM). NP1 concentration was expressed as AU, since its 
authentic standard was not available.  
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compared with the cells that were treated with nobiletin alone for 24 h 
(168,921±19,619 peak area vs. 397,680±27,437 peak area) (Fig. 3D). 
 
3.3 Nobiletin induces G1 arrest in MDA–MB–468 cells 
In order to further explore the mechanism of the antiproliferative action of nobiletin in 
MDA–MB–468 breast cancer cells, flow cytometry analysis was employed following 
treatment of the cells with 10 μM of nobiletin for 24 h. Nobiletin caused G1 arrest in 
the cell cycle of MDA–MB–468 cells that was attenuated in the presence of the CYP1 
inhibitor acacetin (Fig. 4A,B). A significant increase was noted in the population of 
the cells at the G1 phase, following treatment with nobiletin (10 μM) for 24 h 
compared with the control cells treated with DMSO (0.1%) alone (55.9±0.14 vs. 
45.6±1.96, Fig. 4A,B). In the presence of the CYP1 inhibitor acacetin and the 
compound nobiletin, the increase in the cell population at the G1 phase was smaller 
and non significant compared with the control cells (49.03±0.97 vs. 45.6±1.96, Fig. 
4A,B). In contrast to MDA–MB–468 cells, MCF10A cells were not affected by 
nobiletin treatment (10 μM) for 24 h (Fig. 4C,D). Specifically, the population of 
MCF10A cells was not significantly altered following treatment with nobiletin for 48 




Figure 4. Cell cycle analysis of nobiletin in the 2 human breast cell lines MDA–MB–
468 and MCF10A at 24 h. Cell cycle histograms of (A) control MDA–MB–468 cells, 
nobiletin –treated (24 h) MDA–MB–468 cells, nobiletin–treated (24 h) MDA–MB–
468 cells in the presence of the CYP1 inhibitor acacetin (0.5 μM). (B) Distribution of 
the MDA–MB–468 cells in each phase of the cell cycle. (C) Cell cycle histograms of 
control MCF10A cells and nobiletin–treated MCF10A cells. (D) Distribution of the 
MCF10A cells in each phase of the cell cycle. The experiments were conducted at 
least 3 times and error bars indicate STDEV of the mean. * indicate significant 
differences in the cell population of each phase between the control and the treated 
samples (P<0.05). 
   
 17 
4. Discussion 
In the present study, the anticancer activity of nobiletin was investigated in the CYP1 
expressing cell line MDA–MB–468 in terms of cytochrome P450 CYP1 metabolism. 
Nobiletin was metabolized to the conversion product NP1 by a single demethylation 
reaction in the breast cancer cell line, whereas no metabolism was noted in the normal 
breast cell line MCF10A. In addition, nobiletin exhibited submicromolar IC50 in 
MDA–MB–468 cells that was increased in the presence of CYP1 inhibitors, whereas 
it was considerably less active in MCF10A cells. The mechanism of action involved 
inhibition of cell cycle progression at the G1 phase of the cell cycle of MDA–MB–
468 cells, while the data further demonstrated that in the presence of the CYP1 
inhibitor acacetin, the conversion of nobiletin to NP1 was significantly reduced. The 
present study suggests that nobiletin is selectively bioactivated in MDA–MB–468 
breast cancer cells via metabolism by the cytochrome P450 CYP1 family of enzymes. 
The metabolism of nobiletin by CYP1 enzymes was previously described by our 
research group in recombinant enzymes and in MCF7 breast adenocarcinoma cells 
(Surichan et al., 2012). Nobiletin metabolism by CYP1 enzymes resulted in the 
production of the major metabolite NP1 that resulted from a single demethylation step 
in the structure of nobiletin (Surichan et al., 2012). Additional metabolites were 
reported only in the recombinant enzyme assay, whereas in MCF7 cells the 
metabolism of nobiletin involved solely the production of NP1 (Surichan et al., 2012). 
In the current analysis, the metabolite NP1 was evident in the MDA–MB–468 cellular 
samples. However, in contrast to MCF7 cells that are inducible in the presence of a 
CYP1 inducer, MDA–MB–468 cells express constitutively active CYP1 enzymes 
(Androutsopoulos et al., 2009a; Androutsopoulos et al., 2009c; Surichan et al., 2012; 
Androutsopoulos and Tsatsakis, 2014; Androutsopoulos et al., 2008, Wilsher et al., 
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2017). Therefore the metabolism of nobiletin in MDA–MB–468 cells was evident at 
shorter time points compared with that in the MCF7 cell line that requires induction of 
cytochrome CYP1 enzymes by the activation of the AhR (Surichan et al., 2012).  
The identity of NP1 remains unknown, although it may be speculated that it is the 4ʹ–
demethylated derivative of nobiletin. Previous studies conducted on structurally 
similar flavones have demonstrated that the 4ʹ–methoxy position of the B ring is a 
predominant site of metabolism of the flavones by the CYP1 family enzymes, notably 
CYP1A1 (Androutsopoulos et al., 2008; Androutsopoulos et al., 2009a; 
Androutsopoulos and Spandidos 2013; Androutsopoulos et al., 2011). Furthermore, 
the reports by Koga and co–workers have suggested that nobiletin can be metabolized 
by human liver microsomes that include CYP1A2 and to a lesser extent CYP1A1, to 
the 4ʹ,6 and 7 position of the flavones moiety (Koga et al., 2011; Koga et al., 2007). 
The 6 and 7 hydroxylated metabolites originated mainly by CYP3A metabolism, as in 
the presence of the CYP3A inhibitors ketoconazole and troleandomycin their 
formation was attenuated (Koga et al., 2011). By contrast, the production of the 4ʹ–
hydroxylated derivative of nobiletin was attenuated in the presence of the CYP1A2 
inhibitor furafylline and the CYP1A1 inhibitor α–napthoflavone, indicating that this 
conversion was notably catalyzed by the CYP1A family of enzymes (Koga et al., 
2011). This finding agrees with the current report, as MDA–MB–468 cells have been 
shown to express active CYP1A1 (Androutsopoulos et al., 2008). Moreover, the 
contribution of CYP1B1 in the formation of NP1 cannot be ruled out, since this 
enzyme is expressed in MDA–MB–468 cells (Wilsher et al., 2017). 
The inhibition of MDA–MB–468 cellular proliferation by nobiletin metabolism to 
NP1 was mediated via G1 phase cell cycle arrest. This effect was not noted in 
MCF10A cells. Fully methoxylated flavones such as tangeretin and nobiletin have 
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demonstrated cell cycle arrest at the G1 phase of the cell cycle in colon and breast 
cancer cells (Pan et al., 2002; Wu et al., 2017; Chen et al., 2014) via a mechanism 
involving downregulation of cyclin–dependent kinases 2 and 4 activities and 
upregulation of the Cdk inhibitors p21 and p27, as well as induction of apoptosis in 
combination with atorvastatin (Pan et al., 2002; Wu et al., 2017). It is important to 
note that the metabolite of nobiletin 4ʹ–demethyl nobiletin and/or 4ʹ hydroxyl 
nobiletin was capable of inducing G0/G1 arrest in combination with atorvastatin in 
HT–29 colon adenocarcinoma cells (Wu et al., 2017). With regard to breast cancer, 
nobiletin exhibited dose– and time–dependent antitumor activity against 3 different 
subtypes of breast cancer cell lines, namely, MDA–MB–468, SK–BR–3 and MCF7, 
with the greatest inhibition observed against the MDA-MB-468 cell line (Chen et al., 
2014). This type of activity was mediated via induction of cell-cycle arrest at the 
G0/G1 phase by suppressing ERK1/2 activity, with concomitant cyclin-D1 
suppression and p21 up-regulation (Chen et al., 2014). In MDA–MB–468 cells, 
nobiletin further inhibited the activity of AKT and downstream mTOR (Chen et al., 
2014). These data are in agreement with the present study and may explain the 
mechanism of the antiproliferative effect of nobiletin in MDA–MB–468 cells, as a 
result of a combined action of nobiletin and the metabolite NP1. 
With regard to the potency of nobiletin in inhibiting the proliferation of human breast 
cancer cells, this compound exhibited high activity in MDA–MB–468 compared with 
MCF7 cells (Surichan et al., 2012). By contrast, MCF10A cells were notably 
unaffected as the IC50 of nobiletin noted in this cell line was 40 μM. Nobiletin 
exhibited an activation factor of approximately 300–fold in MDA–MB–468 cells 
compared with MDA–MB–468 cells that were treated with nobiletin and CYP1 
inhibitors (30 μM/0.1 μM). A similar pattern was previously noted for the flavonoids 
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sinensetin, genkwanin and eupatorin with IC50 values for MDA–MB–468 and 
MCF10A cells of 0.2, 1.6 and 0.5 μM and 65, 75 and 50 μM, respectively 
(Androutsopoulos et al., 2009d; Androutsopoulos et al., 2008). In the presence of the 
CYP1 inhibitor acacetin, the IC50 values of sinensetin, eupatorin and genkwanin were 
considerably increased (from 0.2 to 13.5 μM for sinensetin, from 0.5 to 15 μM for 
eupatorin and from 1.6 to 12.5 μM for genkwanin) (Androutsopoulos et al., 2009d; 
Androutsopoulos et al., 2008). The present report is in concordance with the 
aforementioned studies that suggest that the degree of methoxylation in the flavone 
moiety enhances the antiproliferative activity of these compounds in MDA–MB–468 
cells due to cytochrome P450 CYP1–metabolism. This is verified by the observation 
that sinensetin and nobiletin that are penta– and hexa–methoxylated flavones 
respectively, exhibited submicromolar IC50 values compared to fully hydroxylated 
flavones such as luteolin and apigenin that indicated higher IC50 values (2 and 22 
μM, respectively) (Androutsopoulos et al., 2009d; Wilsher et al., 2017).  
In conclusion, the present study investigated the anticancer effects of nobiletin with 
regard to CYP1–mediated metabolism in human breast cancer cells. The data 
demonstrate that nobiletin is activated in human breast cancer cells due to CYP1–
mediated conversion to the metabolite NP1 that in turn results in G1 arrest of the 
cells. These effects were absent in normal breast cells that did not express CYP1 
enzymes. The findings suggest that nobiletin may be considered as a selective CYP1–
activated natural product that can be further evaluated for its cancer therapeutic 
efficacy in vivo, in human cancer cells that express active CYP1 enzymes. 
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